Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals

Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals

Background: The TOP2A and ERBB2 genes are co-amplified in about 40% of HER2 positive (HER2+) breast cancers. Oral etoposide (VP16), an inhibitor of topoisomerase-II (encoded by TOP2A), has demonstrated clinical activity in metastatic breast cancer (MBC). The benefit of oral VP16 combined with trastu...

Full description

Bibliographic Details
Main Authors: Ballet, S. (Author), Bellesoeur, A. (Author), Bidard, F.-C (Author), Carton, M. (Author), Chalumeau, C. (Author), Eeckhoutte, A. (Author), Lerebours, F. (Author), Pierga, J.-Y (Author), Stern, M.-H (Author), Vincent-Salomon, A. (Author), Vuagnat, P. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
HER2 metastatic breast cancer
oral etoposide
TOP2A/ERBB2 co-amplification
trastuzumab
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items